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ABSTRACT
Cell-based therapies are promising treatment strategies for a variety of disorders ranging from cancer to spinal cord 
injuries. However, there is a risk of the transplanted cells becoming malignant. As a safeguard against this, suicide 
gene systems can be implemented so that transplanted cells can be eliminated if necessary by administering a 
pro-drug. Herpes simplex virus thymidine kinase (HSV-tk) paired with the pro-drug ganciclovir (GCV) is one of the 
most studied suicide gene systems. However, it can only kill cells that are actively dividing. Here we characterize 
another suicide gene system, nitroreductase (NTR) with its pro-drug metronidazole (MNZ), to investigate where in 
the cell cycle the killing occurs, hypothesizing that it could become an ideal candidate for eliminating transplanted 
cells irrespective of their proliferative status. Murine embryonic stem cells were transfected with vectors expressing 
either HSV-tk or NTR and treated with the corresponding pro-drug. Confocal imaging and FUCCI (fluorescent 
ubiquitination-based cell cycle indicator) were used to identify where in the cell cycle the drug was active2. MNZ 
was found to kill both dividing and non-dividing cells whereas GCV killed only the dividing cells. These results 
suggest that the NTR system may be a valuable addition or complement to HSV-tk.
Les thérapies cellulaires sont des stratégies promettantes en tant que traitements pour une variété de maladies. 
Celles-ci incluent le cancer et les traumatismes médullaires. Cependant, il y a un risque que les cellules implantées 
puissent devenir malignes. Afin de prévenir cela, des systèmes de gènes suicides peuvent être utilisés afin d’éliminer 
les cellules implantées si nécessaires par l’administration d’une prodrogue. La thymidine kinase, une enzyme 
trouvée chez les patients atteint du virus de l’herpès simplex (HSV-tk), utilisée en conjonction avec la prodrogue 
ganciclovir (GCV), est un des systèmes de gènes suicides les plus étudiés. Cependant, il peut seulement tuer les 
cellules qui se divisent activement. Ici, nous caractérisons un autre système de gènes suicidaires, nitroréductase 
(NTR) avec sa prodrogue metronidazole (MNZ), afin d’étudier à quel point dans le cycle cellulaire la tuerie se 
déroule. L’hypothèse est que ce système pourrait être un candidat idéal afin d’éliminer les cellules transplantées, 
peu importe leur statut prolifératif. Des cellules de souche embryonnaires murines ont été transfectées avec 
des vecteurs qui exprimaient soit HSV- tk ou NTR et traitées avec la prodrogue correspondante. La microscopie 
confocale et le système FUCCI (pour fluorescent ubiquitination-based cell cycle indicator) ont été utilisés afin 
d’identifier le point du cycle pendant lequel la drogue était active2. Il a été trouvé que MNZ tuait les cellules qui se 
divisaient et qui ne se divisaient pas, alors que GCV tuait uniquement les cellules qui se divisent. Ces résultats 
suggèrent que le système NTR pourrait être une addition ou un complément utile à HSV-tk. 
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INTRODUCTION 
Stem cell based therapies hold great promise for the 
future of regenerative medicine, and could potentially 
be used to treat a wide variety of diseases, from 
autoimmunity to neurodegeneration to cancer, as shown 
in the literature3. However, if the differentiation process 
of pluripotent cells is not perfect, or if random mutations 
occur during in vitro culture, transplanted cells could 
become cancerous1. Precise control over the presence 
and proliferation of these cells is therefore essential for 
assuring the safety of these therapies.
Suicide genes are genetic tools that enable the 
elimination of cells in vivo by the systematic 
administration of specific drugs to which the largest 
cells exhibit sensitivities. Although initially proposed 
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as a cancer treatment in the 1980s4, they can also 
be used to improve the safety of cell transplantation. 
Transplants harbouring a suicide gene can be 
efficiently and selectively removed from the recipient 
by the administration of a specific drug5. Several 
suicide gene systems have been discovered, each 
acting through different mechanisms, with their own 
set of advantages and disadvantages. For instance, 
to prevent cancer from occurring from transplantation, 
a system that kills all rapidly multiplying cancerous 
cells would be necessary. For other situations, such 
as repairing breakages in trauma injuries, a system 
that can kill all transplanted cells after the breakage 
has been healed would be more advantageous.   
The original and currently most studied suicide system, 
the herpes simplex virus thymidine kinase (HSV-
tk), eliminates actively dividing cells. HSV-tk has a 
high affinity for ganciclovir (GCV)6. GCV and various 
other cellular kinases phosphorylate HSV-tk into a 
triphosphate derivative, which mimics guanosine and 
is able to incorporate itself into DNA. However since it 
is not a nucleoside, DNA synthesis is halted, leading 
to cell apoptosis7. This eliminates dividing cells, as 
they are killed once they undergo mitosis. Since TK 
can only kill dividing cells, it may not be appropriate for 
other kinds of cell therapies. There is an urgent need 
to find alternatives that can also kill quiescent cells, for 
these other types of cell therapies. The nitroreductase 
(NTR)/metronidazole (MNZ) system is considered a 
strong contender for anticancer strategies. Genetically 
modifying tumor cells to express the NTR gene 
activates the MNZ prodrug8. NTR is a common enzyme 
produced by E.coli and other bacterial cells, and MNZ 
is a common antibiotic often used with other antibiotics 
to treat infectious diseases. Similarly to the effect of 
GCV on TK transfected cells, MNZ was found to inhibit 
the proliferation of NTR transfected T-cells8. Previous 
experiments with NTR allude to the fact that this could 
be a marketable suicide system, but to our knowledge, 
there is no information precisely defining where in the 
cell cycle the NTR/MNZ system is active. The aim of 
this work is to investigate the precise temporal action 
of NTR/MNZ within the cell cycle. Finding a suicide 
system that is capable of eliminating all grafted cells 
irrespective of their proliferative state is crucial for the 
field of cell therapies.
MATERIALS AND METHODS
Molecular cloning of transgenes
Vectors expressing TK.007 (TK), an efficient variant 
of HSV-tk9, and Ntro, a high-expression variant of 
nitroreductase10, were constructed using sequences 
from Addgene. AttB sites were added to the ends of TK 
and Ntro for site-specific recombinases to recognize and 
cleave for later amplification. Their cDNA sequences 
were PCR-amplified.    TK and Ntro were cloned into 
pDONR entry vectors using the Gateway BP reaction. 
A Gateway LR reaction was used to insert TK and 
Ntro cDNA respectively into a TAB destination vector 
containing the beta-Geo selectable marker, allowing 
for positive selection with G418 and confirmation of 
transgene expression level by lacZ staining. 
Transfection of transgenes into murine embryonic 
stem cells (ESC)
The Fluorescent Ubiquitination-based Cell Cycle 
Indicator (FUCCI) labels cell cycle stages with different 
fluorescent colors2. We used this to determine the 
cell cycle stage that the TK and Ntro systems were 
capable of eliminating cell expressing their respective 
transgenes. Murine ESC (C57BL/6) were transfected 
with the suicide genes and the FUCCI2 transgene 
using JETPRIME (PolyPlus). A total of 2 ug of DNA was 
transfected. Transfected cells were selected with G418 
and puromycin for 7 days, while adding doxycycline to 
activate the TetO promoter. Colonies from the TK- and 
Ntro-transfected cells were picked into four 96-well 
plates and passaged into triplicates. LacZ staining, 
and fluorescent microscopy was used to select clones 
with the strongest and widest transgene expression. 
Selected clones were clonally expanded and used for 
experiments. 
Treatment of transgenic ESC line with prodrugs to 
induce cell death
TK and Ntro expressing cells were grown under 
differentiating conditions and treated with 100 ug/ml, 150 
ug/ml, 200 ug/ml, and 400 ug/ml of MNZ, and 2 uM, 3 
uM, 4 uM, and 8 uM of GCV respectively, for seven days. 
A dosage curve for GCV and MNZ were conducted prior 
to final imaging to obtain the appropriate concentration 
and time for the final experiment. A timeline of seven 
days was chosen based on the number of days it took 
to kill almost all the TK transgenic cells treated with 
GCV – elimination of all TK cells would make FACS 
analysis impossible. Confocal fluorescent microscopy 
images were taken daily at the same location on each 
well. FACS analysis was used to determine the cell 
cycle position based on FUCCI expression.
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RESULTS
Dosages of 100 ug/ml of MNZ and 2 uM of GCV were 
selected for killing
Initial experiments were conducted with different 
concentrations of MNZ and GCV, respectively, to see 
what range yielded the best results, while using the cells 
transfected with the other suicide gene as a negative 
control. 100 ug/ml of MNZ, and 2 uM of GCV were 
shown to be appropriate base concentrations. 
Proliferation of TK transgenic cells decreased in 
the presence of GCV
Images from the confocal microscope show a decrease 
in proliferating TK transgenic cells when GCV was 
administered. At day 0 of GCV treatment, the number 
of total cells and the ratio between dividing and non-
dividing cells for all drug concentrations were roughly 
the same. After seven days of treatment, we observed 
those that were proliferating (Fig.1). Using the data from 
FACS analysis, it appears that there is a decrease of 
dividing cells and a subsequent relative increase of 
non-dividing cells. While the ratio of dividing to non-
dividing cells after seven days of no drug treatment was 
roughly 5:2, the ratio changed to be roughly 1:3 dividing 
to non-dividing when GCV was administered. This ratio 
was approximately maintained throughout the different 
concentrations of GCV (Fig.3).
The number of both proliferating and non-
proliferating Ntro transgenic cells decreased in the 
presence of MNZ
Confocal microscopy shows a decrease in Ntro 
transgenic cells when MNZ is administered. At day 0 
of MNZ treatment, the total number of cells and the 
ratio between dividing and non-dividing cells for all 
drug concentrations is roughly the same. After seven 
days of MNZ treatment, there are fewer cells than in 
the no-drug control. The ratio between dividing and non-
dividing cells is relatively the same in treated versus non-
treated cells. Proliferating cells appear to be smaller in 
size than the non-proliferating cells (Fig.2). Using data 
from the FACS analysis, the percentage of proliferating 
and non-proliferating cells remains very well preserved 
throughout the different concentrations, at approximately 
a 4:3 ratio. At the 400 ug/ml concentration of MNZ, there 
are nearly equal proliferating cells as non-proliferating 
cells (Fig.4). 
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Figure 1: GCV treated TK/FUCCI transgenic ESC lines at 
in comparison to the no drug treatment control. Green cells 
represent the dividing cells, and red cells represent the non-
dividing cells2. The TK transgenic ESC line undergoing 
GCV treatment showed a considerable decrease in the 
Figure 2: MNZ treated Ntro/FUCCI transgenic ESC lines 
comparison to the no drug treatment control. Green cells 
represent the dividing cells, and red cells represent the non-
dividing cells2. The Ntro transgenic ESC line undergoing 
MNZ treatment showed a decrease in the number of total 
cells, killing both proliferating and non-proliferating cells. 
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GCV efficiently kills TK transgenic cells 
Seven days after drug treatment, the number of 
remaining live cells was determined via flow cytometry. 
We show that the quantity of TK transgenic cells 
dramatically decreases when GCV is administered: 300 
times less compared to the untreated control. There was 
approximately the same number of cells in the different 
concentrations of GCV. There are six times less cells 
when the highest concentration of MNZ was given to TK 
transgenic cells. The 400 ug/ml concentration of MNZ 
substantially decreased the number of TK cells (Fig.5). 
Ntro/MNZ kills less efficiently than the TK/GCV 
Seven days after initiation of drug treatment, the 
numbers of remaining live cells were determined via flow 
cytometry. We show that the number of Ntro transgenic 
cells generally decreases when MNZ is given. There 
was a slight increase of live Ntro cells between 100 ug/
ml and 200 ug/ml concentration of MNZ. However, the 
general trend from the no drug control to the 400 ug/ml 
concentration of MNZ was decreasing, best described 
with an exponentially decaying curve with a coefficient of 
determination (r2) of 0.81129. The exponential curve of 
best fit is modeled by the function f(x)=21775e-0.151x. 
There were approximately 1.3 times less cells with 100 
ug/ml through 200 ug/ml concentrations of MNZ, and 
2 times less cells using 400 ug/ml concentration of 
MNZ in comparison to the no drug control. The highest 
concentration of GCV resulted in the least amount of 
Ntro transgenic cells, approximately 2 times less than 
the no drug control (Fig.6). 
Figure 3: The percentage of RFP positive TK transgenic 
cells (not dividing) and GFP positive cells (dividing) seven 
days after treatment with various concentrations of GCV. 
There is a general decrease of GFP positive dividing cells, 
and a relative increase of RFP positive non-dividing cells.
Figure 4: The percentage of RFP positive Ntro transgenic 
cells non-dividing and GFP positive cells dividing seven 
days after treatment with various concentrations of MNZ. 
The ratio of green dividing cells and red non-dividing 
cells is largely preserved throughout the different MNZ 
concentrations. 
Figure 5: The total number of TK transgenic cells seven 
days after GCV treatments of differing concentrations. 
There is an evident decline in the number of cells when 
GCV is administered.
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DISCUSSION
Recent studies using Ntro/MNZ at a concentration of 
170 ug/ml to eliminate human T-cells8 suggest that Ntro 
and MNZ are a compatible pairing for another suicide 
gene system. The aim of this project was to characterize 
where in the cell cycle the Ntro/MNZ system is active 
and to investigate if this could be a potential alternative 
to the already existing TK/GCV suicide gene system. It 
appears that MNZ kills Ntro transgenic cells, regardless 
of what phase of the cell cycle they are in, as the ratio 
of non-dividing to dividing cells remains very well 
preserved in any of the tested concentrations of MNZ. 
However, the Ntro/MNZ suicide system was not as 
efficient as TK/GCV (Fig.7) (Fig.8). 2 uM of GCV killed 
300 times the TK cells as compared to the no-drug 
control, whereas 100 ug/ml of MNZ only killed 1.3 times 
the Ntro cells as compared to the no-drug control. The 
TK/GCV system is mainly exclusive for proliferating 
cells, while the Ntro/MNZ system is more versatile 
and targets all cells without discriminating based on 
cell cycle phase, regardless if they are dividing or non-
dividing. The highest concentration of MNZ treating 
TK transgenic cells resulted in 83.4% cell death, in 
comparison to the no drug control. While this is less 
toxic than any of the tested concentrations of GCV, 
where 99.6% of the cells resulted in death, theoretically 
MNZ or other pro-drugs should not have an effect on TK 
transgenic cells, as MNZ does not phosphorylate the TK 
gene, therefore not resulting in apoptosis. Similarly, the 
highest concentration of GCV treating Ntro transgenic 
cells resulted in 50% cell death, in comparison to the no 
drug control. Unlike the relationship with MNZ and TK 
transgenic cells, 8 uM of GCV had a higher killing rate 
than any of the tested concentrations of MNZ on Ntro 
transgenic cells. 
GCV was toxic to proliferating TK transgenic cells at 
a concentration of 2 uM, which is comparable to the 
concentration used in literature8. MNZ was toxic to both 
proliferating and non-proliferating cells at a concentration 
of 100 ug/ml. The Ntro/MNZ system acts on all cells – 
dividing and non-dividing, but there is still an active area 
of investigation identifying the mechanisms behind the 
killing. More experiments should be performed, with 
a FACS analysis done on day 0 of treatment, for a 
benchmark of the number of cells and cell cycle phase 
for later comparison at further experiment days. 
Based on our results, Ntro/MNZ hold potential to be 
used for safeguarding any form of cell therapy that 
requires the complete removal of all cells once healing 
has been accomplished. An example of such therapies 
is treatment of spinal cord injury. The transplantation of 
neural progenitor Ntro transgenic cells into the spinal 
cord may be used to repair the damage. Once the repair 
has been accomplished, the transplanted cells may no 
longer be needed. However, there is always a risk that in 
vitro cultured cells may give rise to malignancies. Ntro/
TK could in such cases be used, completely removing 
grafted cells by administration of MNZ. This allows for 
the complete control of transplanted cells with a prodrug, 
which is essential for ensuring and testing the success 
of future cell therapies.  
FUTURE DIRECTIONS
Before the Ntro/MNZ suicide system can move 
forward to clinical trials like TK/GCV, a wider range 
of concentrations need to be tested to maximize the 
efficiency of the killing. This was an in vitro experiment, 
and it would need to be applied to animal models, 
such as the C57BL/6 strain of mice that the cells in this 
experiment were derived from. In vivo experimentation 
could involve transplanting the Ntro-transfected cells 
into the mice and monitoring the growth and death of 
these cells with administration of MNZ. The efficiency of 
different transplantation locations on the mice could also 
be observed. Knowing the versatility of this new system 
is a significant advance in both suicide gene research 
and cell therapy; the next steps would be to learn about 
Figure 6: The total number of Ntro transgenic cells seven 
days after MNZ treatments of differing concentrations. 
There is roughly an exponential decrease in the number of 
cells after administration of MNZ.
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the mechanisms behind the killing, and investigate ways 
to make the system more efficient. 
ABBREVIATIONS
TK – BHerpes simplex virus thymidine kinase 007 
derivative
Ntro – Nitroreductase derivative 
GCV – Ganciclovir
MNZ – Metronidazole 
PCR – Polymerase chain reaction
PB transposon system – PiggyBac transposon system 
FACS – Fluorescent Activated Cell Sorting 
FUCCI – Fluorescent Ubiquitination-based Cell Cycle 
Indicator
LacZ – One gene of the lactose operon, which allows for 
selection with beta-galactosidase 
TetO – Tetracycline-controlled transcriptional activation 
on system. Activated in presence of tetracycline (and 
subsequently doxycycline)
ESC – Embryonic stem cells 
AttB sites – Attachment site in bacterial and phage 
genomes
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